Puncturing The ImClone Hype

Puncturing The ImClone Hype
Could ImClone Systems’ Erbitux be a powerful cancer fighter after all? Maybe.

A new study presented June 1 at a meeting of oncologists seems to boost that contention. But there are still reasons to doubt that Erbitux will be approved soon or that it will eventually be a blockbuster.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.